NCT04031287

Brief Summary

A prospective, longitudinal observational trial in patients with RCDP. Study participants will be evaluated at baseline and approximately every 6 months by the study team. Quality of life, physiologic and functional measurements will be performed. In addition, audiologic recordings and other surveys will be completed at home by parents beginning at baseline and every 3-6 months thereafter.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 13, 2019

Completed
5 days until next milestone

Study Start

First participant enrolled

June 18, 2019

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 24, 2019

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

August 2, 2019

Status Verified

August 1, 2019

Enrollment Period

1.5 years

First QC Date

June 13, 2019

Last Update Submit

August 1, 2019

Conditions

Outcome Measures

Primary Outcomes (30)

  • Medical History

    History collection will be obtained from parents/caretakers and medical records which will be provided or subsequently obtained in a HIPAA compliant manner.

    18 months

  • Body Temperature

    Temperature will be recorded using standard clinical methodology and reported in degrees Celsius.

    18 months

  • Respiratory Rate

    Respiratory rate will be determined by counting number of breaths per minute

    18 months

  • Heart Rate

    Heart rate will be reported as beats per minute

    18 months

  • Blood pressure

    Systolic and diastolic pressure will be reported in mmHG

    18 months

  • Physical Examination: General Appearance

    Reported as "Normal, Abnormal or Not Done". If abnormal, comments will be provided.

    18 months

  • Physical Examination: Head, Eyes, Ears, Nose and Throat

    Reported as "Normal, Abnormal or Not Done". If abnormal, comments will be provided.

    18 months

  • Physical Examination: Cardiovascular

    Reported as "Normal, Abnormal or Not Done". If abnormal, comments will be provided.

    18 months

  • Physical Examination: Dermatologic

    Reported as "Normal, Abnormal or Not Done". If abnormal, comments will be provided.

    18 months

  • Physical Examination: Lymphatic

    Reported as "Normal, Abnormal or Not Done". If abnormal, comments will be provided.

    18 months

  • Physical Examination: Respiratory

    Reported as "Normal, Abnormal or Not Done". If abnormal, comments will be provided.

    18 months

  • Physical Examination: Gastrointestinal

    Reported as "Normal, Abnormal or Not Done". If abnormal, comments will be provided.

    18 months

  • Physical Examination: Genitourinary

    Reported as "Normal, Abnormal or Not Done". If abnormal, comments will be provided.

    18 months

  • Physical Examination: Neurologic System

    Reported as "Normal, Abnormal or Not Done". If abnormal, comments will be provided.

    18 months

  • Physical Examination: FLACC Behavioural Scale

    The standardized FLACC (Faces, Legs, Activity, Consolability) questionnaire will be performed and the score reported.

    18 months

  • Anthropometric Measurement: Length/Height

    Height (Length) will be reported in centimetres

    18 months

  • Anthropometric Measurement: Weight

    Weight will be reported in kg

    18 months

  • Anthropometric Measurement: Head Circumference

    Head Circumference will be reported in cm

    18 months

  • Anthropometric Measurement: Chest Circumference

    Chest Circumference will be reported in cm

    18 months

  • Anthropometric Measurement: Abdominal Circumference

    Abdominal Circumference will be reported in cm

    18 months

  • Observational pain assessment

    Frequency and severity of patient exhibited pain symptoms will be evaluated with two parent-completed questionnaires, The Non-Communicating Children's Pain Checklist- Revised (NCCPC-R) and the Pediatric Pain Scale (PPS)19 (Appendix G). The NCCPC-R is a 7 domain questionnaire that is validated for assessment of pain in children aged 3-18 years who have cognitive and communication impairments. The PPS has 20 domains with a rating scale for each which is also designed to assess symptoms of pain in individuals with communication impairment. Both questionnaires will be completed during the study visits 2 hours after the end of the first morning feed. In addition, the NCCPC-R will be completed by the family 3 months after each visit at the same time interval after the first morning feed.

    18 months

  • Musculoskeletal system assessment

    Musculoskeletal evaluations will be done together by a physiatrist and physical therapy. These assessments will include: assessments of strength, endurance, functional movement and control of extremities, head/neck and trunk. Assessment of muscle tone and passive and active joint range of motion will be made both qualitative and quantitatively for each major joint. Assessment of cognitive engagement will also be made. To assess the motor function and its changes over time, we propose to use Gross Motor Function Measures (GMFM-88), which is a freely available tool validated to evaluate motor skills in cerebral palsy and Down syndrome.

    18 months

  • Nerve conduction

    Patients will be placed in a supine position and electrodes will be placed over the hypothenar eminence, 5th digit and dorsal hand. Stimulations will be done at the wrist and above and below the elbow. These electrodes will be connected to the Natus UltraPro S100 machine. This unit will measure nerve conduction for motor and sensory components. The evaluation will assess nerve latencies, compound motor unit and sensory nerve action potential amplitudes and nerve conduction velocities. These values will be compared to age adjusted normal values for the ulnar nerve.

    18 months

  • Pulmonary function

    A combination of Impulse oscillometry system (IOS), Pneumotachography (PNT) and Respiratory Inductance Plethysmography (RIP) will be used to derive pulmonary indices comparable to spirometry.

    18 months

  • Seizure status by EEG

    Assessments of brain electrical and seizure activity will take place through electroencephalograms (EEGs) at each study visit. Each EEG will last 4 hours and will be scheduled to optimally include both awake and sleep phases. Using the 10-20 International System, the patient's head will be measured and marked for proper electrode placement. Heart rate and rhythm are monitored throughout the EEG by placement of two electrocardiogram electrodes. Electrical activity is then recorded along with a video feed using the Nicolet NicOne acquisition and Xltek brain monitor machines.

    18 months

  • Bone Density and Body Composition by DEXA

    The DEXA scans will be performed in the Medical Imaging Department of Nemours/A.I. duPont Hospital for Children on a Hologic Discovery A QDR bone densitometer (Hologic, Inc., Bedford, MA). Subjects will remove all clothing with metal components prior to DEXA scan to eliminate any possible imaging artifacts; a hospital gown will be provided to the subjects. Standard positioning techniques will be used to acquire the scans. Body sites measured will include the whole body, lumbar spine, and lateral distal femurs of both legs. The following variables will be collected from each scan: bone mineral density (BMD), bone mineral content (BMC), and bone area.

    18 months

  • Plasmalogen Level

    A 100 ul aliquot of the separated serum will be stored at -80 °C and subsequently shipped to Med-Life Discoveries by priority overnight shipment in dry ice. Analyses will include levels of phosphoethanolamines, vinylacylglycerol (VAG), alkylacylglycerol (AAG) and results reported as quantitative concentrations for each metabolite.

    18 months

  • Clinical Chemistry

    Serum will be processed locally for complete blood count (CBC) and standard comprehensive metabolic profile with phosphorus (CMP with PO4).

    18 months

  • Fatigue status

    18 months

  • Gastrointestinal and Feeding status

    To assess level of dysfunction in swallowing, a parent report measure, the Pediatric Assessment Scale for Severe Feeding Problems, designed to assess progress in the development of oral eating skills for children who need prolonged tube feeding will be used. The total score will be used as a quantifiable measure. This questionnaire will be completed during each study visit as well as at home 3 months after each visit. This 13 question interview provides a total score which indicates the level of GI symptom burden.

    18 months

Eligibility Criteria

Age6 Months - 21 Years
Sexall
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients with a diagnosis of RCDP are eligible.

You may qualify if:

  • Diagnosis of RCDP age range 6 months to 21 years
  • A clinical diagnosis of RCDP confirmed with biochemical parameters defined as C16:0 plasmalogen level of less than or equal to 0.75 of the lower limit of the normal reference range AND normal very long chain fatty acid levels.

You may not qualify if:

  • Disease severity: The study physician will decide whether the child is too ill to travel due to chronic or acute severe cardiac or respiratory compromise.
  • Guardian or a care-giver who is not available or not capable of providing accurate information about the patient.
  • Involvement in any other clinical trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alfred I. DuPont Hospital for Children

Wilmington, Delaware, 19803, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples

MeSH Terms

Conditions

Chondrodysplasia Punctata, Rhizomelic

Condition Hierarchy (Ancestors)

Chondrodysplasia PunctataOsteochondrodysplasiasBone Diseases, DevelopmentalBone DiseasesMusculoskeletal DiseasesPeroxisomal DisordersMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Michael Bober, MD

    The Nemours Foundation

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Shawn Ritchie, PhD

CONTACT

Tara Smith, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
18 Months
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 13, 2019

First Posted

July 24, 2019

Study Start

June 18, 2019

Primary Completion

December 1, 2020

Study Completion

June 1, 2021

Last Updated

August 2, 2019

Record last verified: 2019-08

Locations